Palisade bio receives intention to grant from european patent office for lb1148 patent

Carlsbad, ca, march 01, 2023 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (the “company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced that european patent office (epo) has issued a notice of intention to grant for its patent application titled, “administration of serine protease inhibitors to the stomach.” based on the intention to grant notice, the company expects the epo to issue a patent in the second half of 2023.
PALI Ratings Summary
PALI Quant Ranking